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Abstract
Saururus chinensis Baill was reported to inhibit α-glucosidase in vitro and flatten postprandial increase in blood glucose in streptozotocin (STZ)-induced
diabetic rats. We studied the effect of chronic consumption of S. chinensis Baill on blood glucose and lipid profile in STZ-induced diabetic male
rats fed high fat diet. Male rats weighing 100-120 g were fed 30% fat diet with and without 10% freeze-dried leaves of S. chinensis Baill for
7 weeks after 1 week of adaptation. The rats were rendered diabetic by intravenous injection of STZ (60 mg/kg) after 6-week feeding of the assigned
diets. At 1 week after the injection, the rats were sacrificed after an overnight fast. Plasma glucose (380.2 ± 14.4 mg/dL), total cholesterol (93.9
± 7.9 mg/dL) and triglyceride levels (123.6 ± 7.5 mg/dL) of the S. chinensis Baill group were significantly lower than those of the control group
(418.1 ± 12.0 mg/dL, 119.9 ± 9.4 mg/dL, 152.0 ± 10.3 mg/dL, respectively, p<0.05). Chronic consumption of S. chinesis Baill significantly decreased
maltase activity of the small intestinal mucosa (120.1 ± 8.7 U/g protein) compared with the control group (96.8 ± 7.0 U/g protein, p<0.05). These
results suggest that S. chinensis Baill have hypoglycemic and hypolipidemic effects by inhibiting α-glucosidase activity in the animal model of
diabetes mellitus.
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Introduction4)
The prevalence of diabetes mellitus among Koreans is 
increasing due to an aging population, increased urbanization and 
more sedentary lifestyles (King et al., 1998).
  Diabetes mellitus 
results from defects in insulin secretion, insulin action, or both. 
Abnormalities of carbohydrate, lipid, and protein metabolism are 
common in diabetic patients. Cardiovascular disease (CVD) is 
a major complication and the leading cause of premature death 
among patients with diabetes (Centers for Disease Control and 
Prevention, 1999).
Evidence from prospective randomized clinical trials suggests 
that achieving near-normal glycemic control in patients with 
diabetes mellitus is associated with sustained decreased rates of 
diabetes-related cardiovascular complications (The Diabetes 
Control and Complications Trial (DCCT) Research Group, 1993; 
United Kingdom Prospective Diabetes Study (UKPDS), 1998). 
It was also reported that aggressive therapeutic treatment of 
diabetic dyslipidemia reduced the risk of CVD in diabetic patients 
(American Diabetes Association, 2003).
α-Glucosidase is an enzyme involved in the carbohydrate 
digestive process and hence α-glucosidase inhibitors could 
minimize increases in postprandial glucose levels. α-Glucosidase 
inhibitors such as acarbose (Stand et al., 1999), voglibose (Saito 
et al., 1998), and miglitol (Sels et al., 1999) are used as oral 
hypoglycemic agents. It was reported that chronic consumption 
of acarbose could exert hypoglycemic and hypolipidemic effect 
in the patients with diabetes mellitus (Mughal et al., 2000; 
Toeller, 1994). However, chronic use of these agents could result 
in side effects such as flatulence, abdominal cramping, vomiting 
and diarrhea so that their use may be limited (Hanefeld, 1998). 
Therefore, numerous studies have been carried out to isolate α
-glucosidase inhibitors from natural products without side effects 
(Fujita et al., 2001; Matsui et al., 1996; Watanabe et al., 1997). 
In the previous study, methanol extract of S. chinensis Baill 
leaves inhibited yeast α-glucosidase activity in vitro and 
significantly decreased postprandial increase in plasma glucose 
in STZ-induced diabetic rats (Joo et al., 2006). However, hypo-
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Table 1. Diet composition
Ingredient Basal diet S. chinensis Baill diet (g/kg)
Corn starch
1) 90* 90
Casein
2) 255 246
Dextrinized cornstarch
3) 132 132
Sucrose
4) 100 100
Alpha-cellulose
5) 60 5
Mineral mixture
6) 44 44
Vitamin mixture
7) 12.4 12.4
L-Cystine
2) 3.8 3.8
Choline bitratrate
5) 2.8 2.8
Tert-Butyl hydroquinone
8) 0.014 0.014
Soybean oil
4) 70 68
Beef tallow
9) 230 230
S. chinensis Baill leaves
10) -1 0 0
1)  Daesang  Co.,  Korea
2)  ICN  Pharmaceuticals  Inc.,  USA
3)  Dyets.  Inc.,  USA
4)  Cheiljedang  Co.,  Korea
5)  Sigma  Co.,  USA
6)  AIN-93G  Mineral  mix.,  ICN  Pharmaceuticals,  USA
7)  AIN-93G  Vitamin  mix.,  ICN  Pharmaceuticals,  USA
8)  Fluka  Co.,  USA
9) L o t t e  S a m k a n g  C o . ,  K o r e a
10)  Freeze-dried  and  milled
glycemic and hypolipidemic effects of dietary S. chinensis Baill 
were not elucidated. Thus, the primary aim of this study was 
to determine the effect of the chronic consumption of S. chinensis 
Baill leaves on blood glucose and lipid profile and intestinal 
maltase activity in STZ-induced diabetic rats fed high fat diet 
to evaluate its possible use as an antidiabetic agent.
Materials and Methods 
Reagents 
Assay kits for glucose, cholesterol, HDL-cholesterol, and 
triglyceride were purchased from Asan Co (Seoul, Korea). 
Cornstarch was acquired from Daesang Co. (Seoul, Korea). 
Casein, L-cystine, mineral mixture, and vitamin mixture were 
purchased from ICN Pharmaceuticals Inc. (Costa Mesa, CA, 
USA) and tert-butyl hydroquinone from Fluka Co. (Milwaukee, 
WI, USA). Sucrose and soybean oil were obtained from 
Cheiljedang Co. (Seoul, Korea) and beef tallow from Lotte 
Samkang Co. (Seoul, Korea). STZ and other reagent grade 
chemicals were purchased from Sigma Chemical Co (St. Louis, 
MO, USA).
Animals and experimental design
Leaves of S. chinensis Baill was obtained from a local market 
in Busan, Korea and freeze-dried. Proximate analyses of S. 
chinensis Baill leaves were performed according to standard 
AOAC methods (AOAC, 1995).
Male Sprague-Dawley rats weighing between 100 and 120 g 
were purchased from Bio Genomics, Inc. (Seoul, Korea). The rats 
were housed individually in stainless steel wire-bottomed cages 
and located in a room where temperature (23-27℃), humidity 
(50-60%), and lighting cycle (0600-1800 hr light and 1800-0600 
hr dark) were controlled. Body weight and food intake were 
measured three times a week. The rats (n=16) were fed a 
commercial chow diet (Samyang Co., Seoul, Korea) ad libitum 
for 7 days of adaptation period. The animals were randomly 
divided into two groups. Control group was fed 30% fat diet 
and experimental group 30% high fat diet containing 10% 
freeze-dried S. chinesis Baill ad libitum for 7 weeks (Table 1). 
The contents of protein, fat, and dietary fiber of the two diets 
were the same, respectively. After 6-week feeding of the assigned 
diet, the rats were rendered diabetic by intravenous injection of 
STZ (60 mg/kg) in citrate buffer, pH 4.5 into tail vein. At one 
week after the injection, the animals were sacrificed by heart 
puncture after an overnight fast. The small intestine samples were 
collected for further assay. The experiments were performed 
according to the guidelines of animal experimentation approved 
by the Animal Resource Center at Inje University, Korea.
Biochemical analyses
Blood samples were centrifuged at 3000 × g for 15 min and 
plasma was removed and frozen at -70℃ for further analysis. 
Plasma glucose, triglyceride, total cholesterol, and HDL-chole-
sterol were measured by enzymatic methods using commercial 
assay kits. To measure maltase activity, the small intestine was 
excised to remove duodenum. A 10 cm-segment was taken from 
the proximal part of the remaining small intestine. The segment 
was cut longitudinally, washed in 9 g/L of NaCl on ice, and 
then blotted on cheesecloth. The mucosa was scraped off with 
a microscopic slide glass and weighed. The mucosa was 
homogenized in four volumes cold distilled water. The 
homogenates were centrifuged at 12,000 × g for 30 min. The 
supernatants were stored at -70℃ for further analysis. Maltase 
activity was determined according to the method of Dahlqvist 
(Dahlqvist, 1984). Briefly, 100 μL of the supernatant was mixed 
with 100 μL of 0.056 M maltose in 0.1 M maleate buffer (pH 
6.0) and incubated at 37℃ for 60 min. After 0.8 mL of distilled 
water added, the reaction mixture was incubated at 100℃ for 
2 min and cooled in tap water. Five hundred μL of the reaction 
mixture was mixed with 3 mL of Tris-glucose oxidase reagent 
(Sigma Chemical Co, USA), incubated at 37℃ for 60 min, and 
absorbance was read at 420 nm. Maltase activity was determined 
by measuring the amount of glucose released from maltose. 
Protein concentration was determined by the method of Lowry 
et al. using bovine serum albumin as standard (Lowry et al., 
1951). The enzyme activity was expressed as specific activity 
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Table 2. Proximate composition of freeze-dried leaves of S. chinensis Baill
Component Moisture Crude
fat
Crude 
protein
Crude
ash
Dietary 
fiber
% 7.0 2.1 8.8 9.7 54.7
Measurement  was  done  in  triplicate.
Table 3. Body weight, food intake, and feed efficiency ratio of the animals
Control group S. chinensis Baill 
group
Initial body weight (g) 97.1 ± 3.0 96.6 ± 3.3
Body weight at the time of injection 
of STZ (g)
412.4 ± 13.2 414 ± 9.1
Final body weight (g) 402.3 ± 13.5 398.4 ± 15.4
Body weight gain (g/d)  7.3 ± 0.3  7.4 ± 0.2
Food intake (g/d) 19.1 ± 0.3 19.8 ± 0.5
Feed efficiency ratio (%)* 38.5 ± 1.4 37.3 ± 0.7
Values  represent  mean ± SE  (n=8).
*Feed  efficiency  ratio  (%) = (body  weight  gain(g)/food  intake(g)) ×1 0 0
Table 4. Plasma glucose and lipid profile of the animals
Control group S. chinensis Baill group
Glucose (mg/dL)  418.1 ± 12.0  380.2 ± 14.4*
Triglyceride (mg/dL)  152.0 ± 10.3 123.6 ± 7.5*
Total cholesterol (mg/dL) 119.9 ± 9.4  93.9 ± 7.9*
HDL-cholesterol (mg/dL)  47.3 ± 4.2 51.7 ± 6.6
*  p＜0.05
Measurement  was  done  in  triplicate.
Table 5. Maltase activity of the small intestinal mucosa of the animals
Control group S. chinensis Baill group
Specific activity (U/g protein) 120.1 ± 8.7 96.8 ± 7.0*
*  p＜0.05
Measurement  was  done  in  triplicate.
Specific  activity  was  defined  as  mmoles  of  maltose  hydrolyzed/min/g  protein.
Statistical analysis 
All values were expressed as mean ± standard error (SE). All 
statistical analyses were performed using SAS (version 8.02). 
Differences between groups were assessed by Student's t-test and 
significance was defined as p<0.05. 
Results
The proximate composition of freeze-dried leaves of S. 
chinensis Baill is shown in Table 2. The contents of fat, protein, 
ash, and dietary fiber were 2.1%, 8.8%, 9.7%, and 54.7%, 
respectively. 
Body weight and food intake of the rats are shown in Table 
3. Chronic consumption of S. chinensis Baill at the level of 10% 
of high fat diet did not significantly influence body weight, food 
intake and feed efficiency ratio in STZ-induced diabetic rats. The 
effect of S. chinesis Baill on plasma glucose and lipid profile 
are shown in Table 4. The fasting plasma glucose level was 
significantly lower in the S. chinesis Baill group (380.2 ± 14.4 
mg/dL) than in the control group (418.1 ± 12.0 mg/dl, p<0.05, 
Table 4). Consumption of S. chinesis Baill significantly decreased 
plasma triglyceride (123.6 ± 7.5 mg/dL) and total cholesterol 
levels (93.9 ± 7.9 mg/dL) compared with the control group (152.0
± 10.3 mg/dL and 119.9 ± 9.4 mg/dL, respectively, p<0.05). 
However, the plasma HDL-cholesterol level of S. chinesis Baill 
group (51.7 ± 6.6 mg/dL) was not significantly different from 
the control group (47.3 ± 4.2 mg/dL). The effect of chronic 
consumption of S. chinesis Baill on maltase activity of the small 
intestinal mucosa is shown in Table 5. Maltase activity of S. 
chinesis Baill group (120.1 ± 8.7 U/g protein) was significantly 
lower than that of the control group (96.8 ± 7.0 U/g protein, 
p<0.05).
Discussion 
At present, α-glucosidase inhibitors  have been the most 
common oral agents in improving postprandial hyperglycemia 
since they were introduced in the early 1990s.
  However, it is 
well documented that synthetic α-glucosidase inhibitors have 
undesirable side effects, such as flatulence, diarrhea, and 
abdominal cramping (Hanefeld, 1998). Therefore, screening of 
α- glucosidase inhibitors with fewer side effects from natural 
plants is increasing. S. chinensis Baill is a perennial herbaceous 
plant used for the treatment of edema, jaundice, gonorrhea, 
antipyretic, diuretic, and inflammation in Korean folk medicine 
(Chung & Shin, 1990). It was reported that S. chinensis Baill 
leaves have α-glucosidase inhibitory activity in vitro and in vivo 
(Joo  et al., 2006). Chronic consumption of α-glucosidase in-
hibitors was reported to improve metabolism of carbohydrate and 
fat (Balflour & McTavish, 1993; Zavaroni & Reaven, 1981). In 
this study, we investigated the effect of chronic consumption of 
S. chinensis Baill leaves on hyperglycemia and dyslipidemia in 
STZ-induced diabetic rats fed high fat diet. 
The food intake, body weight, and feed efficiency values of 
the S. chinensis Baill group did not significantly differ from the 
control group (Table 3). Chronic feeding of Lonicera japonica 
flowers with α-glucosidase inhibitory activity to rats signifi-
cantly decreased body weight gain, suggesting that α-glucosi-
dase inhibitors may exert an anti-obesity effect (Kwon et al., 
2004). In our study, however, S. chinensis Baill did not show 
any significant influence on body weight of rats fed 30% fat 
diet. Long-term consumption of acarbose did not influence the 
body weight in diabetic patients (Holman et al., 1999). Plasma 
glucose was significantly reduced in the S. chinensis Baill group 
compared to the control group (Table 4). Several clinical trials 
confirmed that chronic consumption of acarbose lowers fasting 
blood glucose significantly in diabetic patients (Balflour & 
McTavish, 1993; Coniff et al., 1995; Holman et al., 1999).
It was suggested that reduced glucose toxicity through decrea-
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of overall glycemic control (Lebovitz, 1998). It has also been 
suggested that acarbose induces a prolonged increase in the 
intestinal hormone glucagon-like peptide-1 (GLP-1) which can 
potentiate the reduction of fasting blood glucose levels 
(Qualmann et al., 1995; Seifarth et al., 1998). It is possible that 
S. chinensis Baill could reduce glucose toxicity by decreasing 
postprandial blood glucose elevations and increasing GLP-1 via 
α-glucosidase inhibitory action, resulting in reduced fasting 
blood glucose levels. Consumption of S. chinensis Baill for 7 
weeks was effective in reducing plasma triglyceride and total 
cholesterol and tended to increase HDL-cholesterol (Table 4). 
It was reported that long-term consumption of acarbose reduced 
blood cholesterol and triglycerides levels in animal model of 
diabetes (Azuma et al., 2006; Yamashita et al., 1984). Chronic 
consumption of touchi with α-glucosidase inhibitory activity 
decreased blood triglyceride and total cholesterol in animal model 
of diabetes (Fujita et al., 2001) and blood triglyceride in diabetic 
patients (Fujita et al., 2003). Chronic consumption of mulberry 
juice and cake powder with α-glucosidase inhibitory activity 
reduced blood triglyceride and total cholesterol and increased 
HDL-cholesterol in STZ-induced diabetic rats (Kwon et al., 
2007). It was suggested that acarbose improves blood lipid profile 
by increasing insulin sensitivity (Azuma et al., 2006). Zavaroni 
& Reaven suggested that chronic α-glucosidase inhibitor lowers 
VLDL-triglyceride secretion resulting in improvement of hyper-
triglyceridemia and hypercholesterolemia (Zavaroni & Reaven, 
1981).
In this study, the consumption of S. chinensis Baill for 7 weeks 
significantly decreased maltase activity of small intestine 
compared with the control group (Table 5). Feeding of acarbose 
at the level of 100 mg/100 g chow to alloxan-induced CBA mice 
for 7 days significantly decreased small intestinal maltase activity 
(22.64 U/g protein) compared with diabetic control group (55.83 
U/g protein, Juretic et al., 2003). It was reported that injection 
of STZ almost doubled maltase activity of middle small intestine 
of rats over 120 U/g protein compared with normal control group 
(Yoo  et al., 2002). Chronic consumption of mulberry juice 
powder with α-glucosidase inhibitory activity at the level of 
0.5%, 1%, and 2% of AIN-76 diet significantly decreased maltase 
activities of proximal, middle, and distal small intestine in 
STZ-induced diabetic rats (Kwon et al., 2007). Reduced in 
maltase activity of small intestine by S. chinensis Baill could 
partially impair digestion of dietary carbohydrates and contribute 
to the control of hyperglycemia.
Achieving near-normal glycemic control and lowering plasma 
lipid levels lead to a decrease in the risk of micro- and macro-
vascular complications of diabetes (DCCT Research Group, 
1993; UKPDS, 1998). Our data demonstrated that S. chinensis 
Baill leaves efficiently improved hyperglycemia, hypertriglyceri-
demia and hypercholesterolemia in STZ-induced diabetic rats fed 
high fat diet. Thus S. chinensis Baill could be effective in 
controlling risks for cardiovascular complications. 
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